Brought to you by 
Domain grants Prexton option on mGluR4 program for Parkinson’s
07 Feb 2017
Executive Summary
Domain Therapeutics SA (focuses on GPCR targets) has licensed CNS start-up Prexton Therapeutics exclusive rights to option its preclinical-stage metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulator (PAM) program for Parkinson’s disease, including lead molecule DT1687.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Domain grants Prexton option on mGluR4 program for Parkinson’s
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice